Iovance Biotherapeutics Inc (HAM:2LB)
€ 3.775 +0.090 (+2.44%) Market Cap: 1.64 Bil Enterprise Value: 1.41 Bil PE Ratio: 0 PB Ratio: 2.54 GF Score: 44/100

Iovance Biotherapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript

Nov 17, 2021 / 04:20PM GMT
Benjamin Jay Burnett
Stifel, Nicolaus & Company, Incorporated, Research Division - Associate

Welcome, everyone, to our next panel. My name is Ben Burnett, biotech analyst at Stifel, and I'm pleased to be joined by Madan Jagasia, SVP of Medical Affairs; and Jean-Marc Bellemin, CFO of Iovance Biotherapeutics. So thank you both for being here.

Jean;Marc Bellemin
Iovance Biotherapeutics, Inc. - CFO & Principal Accounting Officer

Thank you, Ben, for having us.

Benjamin Jay Burnett;Jean;Marc Bellemin
Stifel, Nicolaus & Company, Incorporated, Research Division - Associate

We will do a fireside chat. But obviously, for folks who are dialing in, please feel free to submit questions to the dashboard. I will be monitoring that or e-mail me at [email protected]. So let's just kick it off. Can you maybe just give us a quick update on Iovance where things are, just flag sort of what you think are near-term catalysts that we should be watching out for?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot